COMPANY:

A3P Biomedical

"A landmark study with nine-year follow-up, recently published in European Urology, demonstrates that Stockholm3 can detect aggressive and potentially lethal prostate cancers among men with PSA levels in the 1.5 - 3 ng/ml range. The study showed that these men, who had a positive Stockholm3, were nine times more likely (hazard ratio of 8.8) to have a high-risk biochemical recurrence after treatment than men with PSA 3 ng/ml or higher, and a negative Stockholm3. Approximately 20-30% of men aged 50-75 years have a PSA between 1.5 – 3 ng/ml."

"The National Comprehensive Cancer Network® (NCCN®) is a leading US authority in clinical practice standards for cancer care. Stockholm3 has been added to the NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer Early Detection, Version 2.2025 [1]. The NCCN guidelines state the probability of high-grade cancer (Grade Group ≥2) may be further defined prior to initial biopsy utilizing tools such as Stockholm3. Stockholm3 is categorized as a 2A-level recommendation indicating uniform consensus among NCCN panel experts that Stockholm3 is an appropriate option based on current evidence."

"A new article, published in European Urology Oncology highlights the effectiveness of Stockholm3 in improving repeat screening for prostate cancer. The clinical study demonstrated that using Stockholm3 instead of traditional prostate-specific antigen (PSA) testing increased detection of clinically significant cancers by 31%, without increasing the need for magnetic resonance imaging."

"A3P Biomedical and Labor Dr. Wisplinghoff, one of Germany's largest and most renowned medical laboratories, are excited to announce that Stockholm3, for early detection of prostate cancer, has now been launched and is available in Germany."

"A3P Biomedical...has entered a strategic partnership with labor team...Effective November 1, 2024, this collaboration will make Stockholm3, a pioneering blood-based diagnostic for early detection of aggressive prostate cancer, available to men throughout Switzerland."

"Stockholm3 has been independently, externally validated at the Martini Klinik, the world-renowned prostate cancer center in Hamburg, Germany. The Martini validation study demonstrated results consistent with previous Stockholm3 studies, achieving a 52 percent reduction of unnecessary biopsies."

"Findings from the SEPTA trial demonstrate the utility and generalizability of Stockholm3 in reducing unneeded biopsies and detecting prostate cancer (PCa) in Asian, Black, Hispanic, and White men, representing an important improvement in the harm-benefit tradeoffs in PCa detection."

"A3P Biomedical AB...and BioAgilytix...are excited to announce that Stockholm3 for early detection of prostate cancer is now commercially available as a Lab Developed Test (LDT) throughout the United States."

"A recent study published in European Urology Open Science demonstrates that incorporating Stockholm3 into prostate cancer diagnostics can significantly reduce healthcare costs. Stockholm3, which combines genetic-, protein- and clinical markers, also provides a more accurate risk stratification for developing significant prostate cancer compared to PSA testing alone."

"The annual 2024 European Association of Urology (EAU) meeting was held in Paris from April 5 – 8. More sophisticated risk adapted prostate cancer strategies was a focus area, including six abstracts evaluating Stockholm3 in populations across Europe and North America. An abstract utilizing a baseline Stockholm3 score to predict biochemical recurrence after prostatectomy was awarded best abstract in the prostate cancer biopsy indication session."

"In 2002, Region Stockholm and Region Gotland (the Region) began a joint three-year project by offering organised prostate cancer testing (OPT) to all 50-year-old men living in the Region. In 2024, an evaluation of the Stockholm3 test will be made in a research project at Karolinska Institutet in collaboration with OPT."

"In the latest edition of European Urology Open Sciences, the Prostate Cancer Center at Capio St. Göran’s Hospital is highlighted for its well-invested and structured model for prostate cancer diagnostics. This model, based on Stockholm3 combined with MRI and targeted biopsies has been shown to significantly improve the diagnostic outcome and health economics."